390 related articles for article (PubMed ID: 21887711)
21. The Lewy body in Parkinson's disease: molecules implicated in the formation and degradation of alpha-synuclein aggregates.
Wakabayashi K; Tanji K; Mori F; Takahashi H
Neuropathology; 2007 Oct; 27(5):494-506. PubMed ID: 18018486
[TBL] [Abstract][Full Text] [Related]
22. Familial Mutations and Post-translational Modifications of UCH-L1 in Parkinson's Disease and Neurodegenerative Disorders.
Lee YC; Hsu SD
Curr Protein Pept Sci; 2017; 18(7):733-745. PubMed ID: 26899237
[TBL] [Abstract][Full Text] [Related]
23. Role of post-translational modifications in modulating the structure, function and toxicity of alpha-synuclein: implications for Parkinson's disease pathogenesis and therapies.
Oueslati A; Fournier M; Lashuel HA
Prog Brain Res; 2010; 183():115-45. PubMed ID: 20696318
[TBL] [Abstract][Full Text] [Related]
24. [Relationship between alpha-synuclein and Parkinson's disease].
Nishioka K; Hattori N
Brain Nerve; 2007 Aug; 59(8):825-30. PubMed ID: 17713118
[TBL] [Abstract][Full Text] [Related]
25. Binding of alpha-synuclein to brain vesicles is abolished by familial Parkinson's disease mutation.
Jensen PH; Nielsen MS; Jakes R; Dotti CG; Goedert M
J Biol Chem; 1998 Oct; 273(41):26292-4. PubMed ID: 9756856
[TBL] [Abstract][Full Text] [Related]
26. Is Cell Death Primary or Secondary in the Pathophysiology of Idiopathic Parkinson's Disease?
Schulz-Schaeffer WJ
Biomolecules; 2015 Jul; 5(3):1467-79. PubMed ID: 26193328
[TBL] [Abstract][Full Text] [Related]
27. The contribution of alpha synuclein to neuronal survival and function - Implications for Parkinson's disease.
Benskey MJ; Perez RG; Manfredsson FP
J Neurochem; 2016 May; 137(3):331-59. PubMed ID: 26852372
[TBL] [Abstract][Full Text] [Related]
28. Accelerated formation of alpha-synuclein oligomers by concerted action of the 20S proteasome and familial Parkinson mutations.
Lewis KA; Yaeger A; DeMartino GN; Thomas PJ
J Bioenerg Biomembr; 2010 Feb; 42(1):85-95. PubMed ID: 20148295
[TBL] [Abstract][Full Text] [Related]
29. Cardiac sympathetic denervation in Parkinson's disease linked to SNCA duplication.
Orimo S; Uchihara T; Nakamura A; Mori F; Ikeuchi T; Onodera O; Nishizawa M; Ishikawa A; Kakita A; Wakabayashi K; Takahashi H
Acta Neuropathol; 2008 Nov; 116(5):575-7. PubMed ID: 18751989
[No Abstract] [Full Text] [Related]
30. Α-synuclein misfolding and Parkinson's disease.
Breydo L; Wu JW; Uversky VN
Biochim Biophys Acta; 2012 Feb; 1822(2):261-85. PubMed ID: 22024360
[TBL] [Abstract][Full Text] [Related]
31. Neurotoxic conversion of beta-synuclein: a novel approach to generate a transgenic mouse model of synucleinopathies?
Fujita M; Sekigawa A; Sekiyama K; Sugama S; Hashimoto M
J Neurol; 2009 Aug; 256 Suppl 3():286-92. PubMed ID: 19711118
[TBL] [Abstract][Full Text] [Related]
32. The role of alpha-synuclein gene multiplications in early-onset Parkinson's disease and dementia with Lewy bodies.
Hofer A; Berg D; Asmus F; Niwar M; Ransmayr G; Riemenschneider M; Bonelli SB; Steffelbauer M; Ceballos-Baumann A; Haussermann P; Behnke S; Krüger R; Prestel J; Sharma M; Zimprich A; Riess O; Gasser T
J Neural Transm (Vienna); 2005 Sep; 112(9):1249-54. PubMed ID: 15622440
[TBL] [Abstract][Full Text] [Related]
33. α-Synuclein misfolding and aggregation: Implications in Parkinson's disease pathogenesis.
Mehra S; Sahay S; Maji SK
Biochim Biophys Acta Proteins Proteom; 2019 Oct; 1867(10):890-908. PubMed ID: 30853581
[TBL] [Abstract][Full Text] [Related]
34. LRRK2 protein is a component of Lewy bodies.
Zhu X; Siedlak SL; Smith MA; Perry G; Chen SG
Ann Neurol; 2006 Nov; 60(5):617-618. PubMed ID: 16847950
[No Abstract] [Full Text] [Related]
35. Alpha-synuclein structure and Parkinson's disease - lessons and emerging principles.
Meade RM; Fairlie DP; Mason JM
Mol Neurodegener; 2019 Jul; 14(1):29. PubMed ID: 31331359
[TBL] [Abstract][Full Text] [Related]
36. α-Synuclein BAC transgenic mice exhibit RBD-like behaviour and hyposmia: a prodromal Parkinson's disease model.
Taguchi T; Ikuno M; Hondo M; Parajuli LK; Taguchi K; Ueda J; Sawamura M; Okuda S; Nakanishi E; Hara J; Uemura N; Hatanaka Y; Ayaki T; Matsuzawa S; Tanaka M; El-Agnaf OMA; Koike M; Yanagisawa M; Uemura MT; Yamakado H; Takahashi R
Brain; 2020 Jan; 143(1):249-265. PubMed ID: 31816026
[TBL] [Abstract][Full Text] [Related]
37. Distinct Effects of Familial Parkinson's Disease-Associated Mutations on α-Synuclein Phase Separation and Amyloid Aggregation.
Xu B; Fan F; Liu Y; Liu Y; Zhou L; Yu H
Biomolecules; 2023 Apr; 13(5):. PubMed ID: 37238596
[TBL] [Abstract][Full Text] [Related]
38. Threonine 53 in alpha-synuclein is conserved in long-living non-primate animals.
Larsen K; Hedegaard C; Bertelsen MF; Bendixen C
Biochem Biophys Res Commun; 2009 Sep; 387(3):602-5. PubMed ID: 19619507
[TBL] [Abstract][Full Text] [Related]
39. Neurotoxic or neuroprotective: Post-translational modifications of α-synuclein at the cross-roads of functions.
Gadhavi J; Patel M; Bhatia D; Gupta S
Biochimie; 2022 Jan; 192():38-50. PubMed ID: 34582997
[TBL] [Abstract][Full Text] [Related]
40. Loss of functional alpha-synuclein: a toxic event in Parkinson's disease?
Kanaan NM; Manfredsson FP
J Parkinsons Dis; 2012; 2(4):249-67. PubMed ID: 23938255
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
